123 related articles for article (PubMed ID: 17366681)
1. A complex pattern of melanonychia and onycholysis after treatment with pemetrexed for lung cancer.
Dasanu CA; Wiernik PH; Vaillant J; Alexandrescu DT
Skinmed; 2007; 6(2):95-6. PubMed ID: 17366681
[TBL] [Abstract][Full Text] [Related]
2. A rare manifestation of nail changes with docetaxel therapy.
Halvorson CR; Erickson CL; Gaspari AA
Skinmed; 2010; 8(3):179-80. PubMed ID: 21137627
[TBL] [Abstract][Full Text] [Related]
3. Pemetrexed-induced eyelid edema in lung cancer.
Martins-Filho PR; Kameo SY; Mascarenhas-Oliveira AC; Vieira NF; Azevedo E
J Craniofac Surg; 2013 Jul; 24(4):e401-3. PubMed ID: 23851735
[TBL] [Abstract][Full Text] [Related]
4. Pemetrexed versus docetaxel in second line non-small-cell lung cancer: results and subsets analyses of a multi-center, randomized, exploratory trial in Chinese patients.
Li R; Sun L; Wang J; Qian J; Wang Z; Jiao X
Pulm Pharmacol Ther; 2012 Oct; 25(5):364-70. PubMed ID: 22766314
[TBL] [Abstract][Full Text] [Related]
5. The optimal duration of vitamin supplementation prior to the first dose of pemetrexed in patients with non-small-cell lung cancer.
Kim YS; Sun JM; Ahn JS; Ahn MJ; Park K
Lung Cancer; 2013 Aug; 81(2):231-5. PubMed ID: 23683535
[TBL] [Abstract][Full Text] [Related]
6. Unsuccessful rechallenge with pemetrexed after a previous radiation recall dermatitis.
Barlési F; Tummino C; Tasei AM; Astoul P
Lung Cancer; 2006 Dec; 54(3):423-5. PubMed ID: 17049669
[TBL] [Abstract][Full Text] [Related]
7. Pemetrexed: new drug. Pleural mesothelioma: a first encouraging trial.
Prescrire Int; 2005 Dec; 14(80):212-4. PubMed ID: 16400741
[TBL] [Abstract][Full Text] [Related]
8. Pemetrexed as a possible cause of severe rhabdomyolysis in the treatment of lung cancer.
Huang MS; Tsai JR; Shen MC; Chou SH; Yang CJ
Lung Cancer; 2012 Jun; 76(3):491-2. PubMed ID: 22405568
[TBL] [Abstract][Full Text] [Related]
9. Alveolar hemorrhage associated with pemetrexed administration.
Kurimoto R; Sekine I; Iwasawa S; Sakaida E; Tada Y; Tatsumi K; Takahashi Y; Nakatani Y; Imai C; Takiguchi Y
Intern Med; 2015; 54(7):833-6. PubMed ID: 25832952
[TBL] [Abstract][Full Text] [Related]
10. Maintenance therapy with pemetrexed versus docetaxel after induction therapy with carboplatin and pemetrexed in chemotherapy-naïve patients with advanced non-squamous non-small-cell lung cancer: a randomized, phase II study.
Karayama M; Inui N; Kuroishi S; Yokomura K; Toyoshima M; Shirai T; Masuda M; Yamada T; Yasuda K; Suda T; Chida K
Cancer Chemother Pharmacol; 2013 Aug; 72(2):445-52. PubMed ID: 23807323
[TBL] [Abstract][Full Text] [Related]
11. Adenocarcinoma has an excellent outcome with pemetrexed treatment in Korean patients: a prospective, multicenter trial.
Lee HY; Ahn MJ; Park YH; Ahn JS; Kim BS; Kim HK; Kim HT; Ryoo HM; Bae SH; Lee SS; Choi K; Hong DS; Lee KH; Kwon JH; Choi IS; Kim BS; Lee NS; Gong SJ; Park K
Lung Cancer; 2009 Dec; 66(3):338-43. PubMed ID: 19299031
[TBL] [Abstract][Full Text] [Related]
12. Toxic epidermal necrolysis related to pemetrexed and carboplatin with vitamin B12 and folic acid supplementation for advanced non-small cell lung cancer.
Bosch-Barrera J; Gaztañaga M; Ceballos J; Pérez-Gracia JL; López-Picazo JM; García-Foncillas J; Ferrer M; Sanz ML; Pretel M; Idoate MA; Gil-Bazo I
Onkologie; 2009 Oct; 32(10):580-4. PubMed ID: 19816075
[TBL] [Abstract][Full Text] [Related]
13. [Clinical efficacy of vitamin support in lung adenocarcinoma patients treated with pemetrexed second-line chemotherapy].
Zeng X; Zhou C; Ouyang M; Qin Y; Yang H; Peng Y; Liu S
Zhonghua Zhong Liu Za Zhi; 2015 Nov; 37(11):868-72. PubMed ID: 26887521
[TBL] [Abstract][Full Text] [Related]
14. Plasma homocysteine levels and hematological toxicity in NSCLC patients after the first cycle of pemetrexed under folate supplementation.
Tanaka H; Horiike A; Sakatani T; Saito R; Yanagitani N; Kudo K; Ohyanagi F; Horai T; Nishio M
Anticancer Drugs; 2015 Jun; 26(5):573-8. PubMed ID: 25714250
[TBL] [Abstract][Full Text] [Related]
15. Concomitant chemoradiotherapy using pemetrexed and carboplatin for unresectable stage III non-small cell lung cancer (NSCLC): preliminary results of a phase II study.
Xu Y; Ma S; Ji Y; Sun X; Jiang H; Chen J; Du X; Zheng Y; Qiu G
Lung Cancer; 2011 Jun; 72(3):327-32. PubMed ID: 21056507
[TBL] [Abstract][Full Text] [Related]
16. Intermittent erlotinib in combination with pemetrexed: phase I schedules designed to achieve pharmacodynamic separation.
Davies AM; Ho C; Beckett L; Lau D; Scudder SA; Lara PN; Perkins N; Gandara DR
J Thorac Oncol; 2009 Jul; 4(7):862-8. PubMed ID: 19494788
[TBL] [Abstract][Full Text] [Related]
17. Survival without common toxicity criteria grade 3/4 toxicity for pemetrexed compared with docetaxel in previously treated patients with advanced non-small cell lung cancer (NSCLC): a risk-benefit analysis.
Pujol JL; Paul S; Chouaki N; Peterson P; Moore P; Berry DA; Salzberg M
J Thorac Oncol; 2007 May; 2(5):397-401. PubMed ID: 17473654
[TBL] [Abstract][Full Text] [Related]
18. A randomized phase 2 trial of erlotinib versus pemetrexed as second-line therapy in the treatment of patients with advanced EGFR wild-type and EGFR FISH-positive lung adenocarcinoma.
Li N; Ou W; Yang H; Liu QW; Zhang SL; Wang BX; Wang SY
Cancer; 2014 May; 120(9):1379-86. PubMed ID: 24481719
[TBL] [Abstract][Full Text] [Related]
19. Pemetrexed as a component of first-, second- and third- line chemotherapy in treating patients with metastatic lung adenocarcinoma.
Huang XE; Tian GY; Cao J; Xu X; Lu YY; Wu XY; Liu J; Shi L; Xiang J
Asian Pac J Cancer Prev; 2014 Jan; 14(11):6663-7. PubMed ID: 24377585
[TBL] [Abstract][Full Text] [Related]
20. Pemetrexed: a multitargeted antifolate.
Rollins KD; Lindley C
Clin Ther; 2005 Sep; 27(9):1343-82. PubMed ID: 16291410
[TBL] [Abstract][Full Text] [Related]
[Next] [New Search]
